Human epidermal growth factor receptor 2-positive (HER2+) and triple-negative breast
cancer patients often present with brain metastasis. HER2-targeted therapies have not been …

Simple Summary Breast cancer, the most common malignant tumor among women
worldwide, remains an incurable disease once it has spread to the brain. Past research has …

Abstract Background Brain metastases (BrM) incidence is 25% to 50% in women with
advanced human epidermal growth factor receptor 2 (HER2)‐positive breast cancer …

Breast cancer occurs in approximately 1 in 8 women and 1 in 37 women with breast cancer
succumbed to the disease. Over the past decades, new diagnostic tools and treatments …

As the global incidence of cancer has increased, brain metastases now appear in 8%–10%
of all cases. Major advances in neuroimaging have led to increased detection of brain …

Breast cancer brain metastases (BCBMs) are the second most frequent secondary central
nervous system metastases following those associated with non-small-cell lung cancer. It is …

Breast cancer is the second-leading cause of metastatic disease in the central nervous
system (CNS). Recent advances in the biological understanding of breast cancer have …

The brain is the most common site of first metastasis for patients with HER2-positive breast
cancer treated with HER2-targeting drugs. However, the development of effective therapies …

Chen et al explored clinicopathological features and prognostic factors, revealing advanced
tumor stage, lung metastases, HER-2 overexpression, and triple-negative status as key …

Abstract Purpose: The presence of Her2 amplification is associated with an increased risk of
developing brain metastases. Brain metastases in breast cancer can be particularly …